Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Paroxysmal Nocturnal Hemoglobinuria Treatment Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 ACH-4471
      • 1.3.3 ALN-CC5
      • 1.3.4 ALXN-1210
      • 1.3.5 AMY-101
      • 1.3.6 APL-2
      • 1.3.7 Others
    • 1.4 Market Segment by Application
      • 1.4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Application (2019-2025)
      • 1.4.2 Hospital
      • 1.4.3 Clinic
      • 1.4.4 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size
      • 2.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue 2014-2025
      • 2.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales 2014-2025
    • 2.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Growth Rate by Regions
      • 2.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales by Regions 2014-2019
      • 2.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Sales by Manufacturers
      • 3.1.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Sales by Manufacturers 2014-2019
      • 3.1.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Manufacturers (2014-2019)
      • 3.2.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Price by Manufacturers
    • 3.4 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria Treatment Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Paroxysmal Nocturnal Hemoglobinuria Treatment Market
    • 3.6 Key Manufacturers Paroxysmal Nocturnal Hemoglobinuria Treatment Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 ACH-4471 Sales and Revenue (2014-2019)
      • 4.1.2 ALN-CC5 Sales and Revenue (2014-2019)
      • 4.1.3 ALXN-1210 Sales and Revenue (2014-2019)
      • 4.1.4 AMY-101 Sales and Revenue (2014-2019)
      • 4.1.5 APL-2 Sales and Revenue (2014-2019)
      • 4.1.6 Others Sales and Revenue (2014-2019)
    • 4.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share by Type
    • 4.3 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Type
    • 4.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales by Application

    6 United States

    • 6.1 United States Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Company
    • 6.2 United States Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Type
    • 6.3 United States Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Application

    7 European Union

    • 7.1 European Union Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Company
    • 7.2 European Union Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Type
    • 7.3 European Union Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Application

    8 China

    • 8.1 China Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Company
    • 8.2 China Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Type
    • 8.3 China Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Company
    • 9.2 Rest of World Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Type
    • 9.3 Rest of World Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Application
    • 9.4 Rest of World Paroxysmal Nocturnal Hemoglobinuria Treatment Breakdown Data by Countries
      • 9.4.1 Rest of World Paroxysmal Nocturnal Hemoglobinuria Treatment Sales by Countries
      • 9.4.2 Rest of World Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Achillion Pharmaceuticals Inc
      • 10.1.1 Achillion Pharmaceuticals Inc Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Paroxysmal Nocturnal Hemoglobinuria Treatment
      • 10.1.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Product Introduction
      • 10.1.5 Achillion Pharmaceuticals Inc Recent Development
    • 10.2 Akari Therapeutics Plc
      • 10.2.1 Akari Therapeutics Plc Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Paroxysmal Nocturnal Hemoglobinuria Treatment
      • 10.2.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Product Introduction
      • 10.2.5 Akari Therapeutics Plc Recent Development
    • 10.3 Alexion Pharmaceuticals Inc
      • 10.3.1 Alexion Pharmaceuticals Inc Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Paroxysmal Nocturnal Hemoglobinuria Treatment
      • 10.3.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Product Introduction
      • 10.3.5 Alexion Pharmaceuticals Inc Recent Development
    • 10.4 Alnylam Pharmaceuticals Inc
      • 10.4.1 Alnylam Pharmaceuticals Inc Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Paroxysmal Nocturnal Hemoglobinuria Treatment
      • 10.4.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Product Introduction
      • 10.4.5 Alnylam Pharmaceuticals Inc Recent Development
    • 10.5 Amgen Inc
      • 10.5.1 Amgen Inc Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Paroxysmal Nocturnal Hemoglobinuria Treatment
      • 10.5.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Product Introduction
      • 10.5.5 Amgen Inc Recent Development
    • 10.6 Apellis Pharmaceuticals Inc
      • 10.6.1 Apellis Pharmaceuticals Inc Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Paroxysmal Nocturnal Hemoglobinuria Treatment
      • 10.6.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Product Introduction
      • 10.6.5 Apellis Pharmaceuticals Inc Recent Development
    • 10.7 F. Hoffmann-La Roche Ltd
      • 10.7.1 F. Hoffmann-La Roche Ltd Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Paroxysmal Nocturnal Hemoglobinuria Treatment
      • 10.7.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Product Introduction
      • 10.7.5 F. Hoffmann-La Roche Ltd Recent Development
    • 10.8 ISU ABXIS Co Ltd
      • 10.8.1 ISU ABXIS Co Ltd Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Paroxysmal Nocturnal Hemoglobinuria Treatment
      • 10.8.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Product Introduction
      • 10.8.5 ISU ABXIS Co Ltd Recent Development
    • 10.9 Novartis AG
      • 10.9.1 Novartis AG Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Paroxysmal Nocturnal Hemoglobinuria Treatment
      • 10.9.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Product Introduction
      • 10.9.5 Novartis AG Recent Development
    • 10.10 NovelMed Therapeutics Inc
      • 10.10.1 NovelMed Therapeutics Inc Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Paroxysmal Nocturnal Hemoglobinuria Treatment
      • 10.10.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Product Introduction
      • 10.10.5 NovelMed Therapeutics Inc Recent Development
    • 10.11 Omeros Corp
    • 10.12 Ra Pharmaceuticals Inc
    • 10.13 Regeneron Pharmaceuticals Inc
    • 10.14 Regenesance BV

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Channels
      • 11.2.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Distributors
    • 11.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Customers

    12 Market Forecast

    • 12.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales and Revenue Forecast 2019-2025
    • 12.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Forecast by Type
    • 12.3 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Forecast by Application
    • 12.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Forecast by Regions
      • 12.4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Paroxysmal Nocturnal Hemoglobinuria Treatment is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Paroxysmal Nocturnal Hemoglobinuria Treatment.

      This report studies the global market size of Paroxysmal Nocturnal Hemoglobinuria Treatment, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Paroxysmal Nocturnal Hemoglobinuria Treatment sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Achillion Pharmaceuticals Inc
      Akari Therapeutics Plc
      Alexion Pharmaceuticals Inc
      Alnylam Pharmaceuticals Inc
      Amgen Inc
      Apellis Pharmaceuticals Inc
      F. Hoffmann-La Roche Ltd
      ISU ABXIS Co Ltd
      Novartis AG
      NovelMed Therapeutics Inc
      Omeros Corp
      Ra Pharmaceuticals Inc
      Regeneron Pharmaceuticals Inc
      Regenesance BV

      Market Segment by Product Type
      ACH-4471
      ALN-CC5
      ALXN-1210
      AMY-101
      APL-2
      Others

      Market Segment by Application
      Hospital
      Clinic
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Paroxysmal Nocturnal Hemoglobinuria Treatment status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Paroxysmal Nocturnal Hemoglobinuria Treatment manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Paroxysmal Nocturnal Hemoglobinuria Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now